3/29/2023 10:06:11 AM
Wedbush Reiterates ARS Pharmaceuticals, Inc. (SPRY) At Outperform With $17 Price Target
3/27/2023 4:48:47 PM
Wedbush Is Cutting ARS Pharmaceuticals, Inc. (SPRY) FY23 Rev. Estimate To 8.8 M From 23.5 M
3/27/2023 4:48:30 PM
Wedbush Is Lowering ARS Pharmaceuticals, Inc. (SPRY) Q4 23 Rev. Estimate To 5.9 M From 15.3 M
3/27/2023 4:48:11 PM
Wedbush Is Lowering ARS Pharmaceuticals, Inc. (SPRY) Q3 23 Rev. Estimate To 2.9 M From 8.2 M
3/27/2023 4:47:33 PM
Wedbush Is Cutting ARS Pharmaceuticals, Inc. (SPRY) FY23 Estimate To -0.71 From -0.37
3/27/2023 4:47:07 PM
Wedbush Is Cutting ARS Pharmaceuticals, Inc. (SPRY) Q4 23 Estimate To -0.15 From -0.01
3/27/2023 4:46:52 PM
Wedbush Is Cutting ARS Pharmaceuticals, Inc. (SPRY) Q3 23 Estimate To -0.17 From -0.07
3/27/2023 4:46:35 PM
Wedbush Is Cutting ARS Pharmaceuticals, Inc. (SPRY) Q2 23 Estimate To -0.20 From -0.15
3/27/2023 4:46:05 PM
Wedbush Is Cutting ARS Pharmaceuticals, Inc. (SPRY) Q1 23 Estimate To -0.19 From -0.14
3/27/2023 4:45:21 PM
Wedbush Reiterates ARS Pharmaceuticals, Inc. (SPRY) At Outperform With $17 Price Target